FAST NEWS: BeiGene’s Lymphoma Drug Recommended to Enter European Regulator

The latest: BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday that its Zanubrutinib drug has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which recommended approval for the drug to treat adults with marginal zone lymphoma. Looking up: Following the positive opinion, the European Commission will consider BeiGene’s marketing application, with a final decision expected within 67 days. If approved for marketing, the drug is expected to enter the world’s largest market with 29 member countries. Take Note: Marginal zone…

Read More »

Boqii Barks With Latest Earnings Report, But Investors Beg for Profits

Online pet community operator’s margins improved sharply in the three months to June, bringing it closer to elusive profits Key Takeaways: Boqii’s revenue dropped slightly in the three months to June, though business for its self-operated mall rose by 20% Company could face delisting if it can’t bring its market value above $50 million – more than double the current level – by early 2024 By Doug Young If there’s one group that suffered the most during China’s ongoing Covid lockdowns, it’s arguably the thousands of pets that call major…

Read More »

Lifted by Southeast Asia Growth, Insurer FWD Seeks IPO Safe Landing

Hong Kong tycoon Richard Li’s Asia-focused insurance company, FWD Group, has filed again for an IPO that reportedly aims to raise $1 billion Key Takeaways: FWD has switched its focus from opportunities in China to the growth potential in Southeast Asia as its main IPO selling point for investors The company’s listing was delayed in May this year due to bumpy market conditions, and it is still beset by uncertainty, with sluggish Hong Kong stocks and a likely swing from profit to loss this year By Ken Lo FWD Group…

Read More »